Profile data is unavailable for this security.
About the company
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
- Revenue in USD (TTM)1.18bn
- Net income in USD122.00m
- Incorporated2025
- Employees1.03k
- LocationIndivior Pharmaceuticals Inc10710 Midlothian TurnpikeSuite 125, North ChesterfieldDOVER 23235United StatesUSA
- Phone+1 (804) 379-1090
- Websitehttps://www.indivior.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | 1.00bn | 22.39m | 2.65bn | 733.00 | 167.64 | 7.08 | 110.50 | 2.64 | 0.1235 | 0.1235 | 7.90 | 2.92 | 1.02 | 0.913 | 3.18 | 1,369,416.00 | 2.28 | -48.52 | 3.09 | -62.30 | 89.81 | 87.55 | 2.23 | -90.49 | 2.70 | 1.78 | 0.5516 | -- | 28.46 | 31.98 | 111.31 | -- | -43.47 | -- |
| Liquidia Corp | 69.22m | -121.85m | 2.69bn | 157.00 | -- | 121.81 | -- | 38.89 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.81bn | 979.00 | -- | 6.17 | -- | 7.19 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 588.99m | 214.33m | 2.92bn | 182.00 | 14.18 | 3.07 | 11.56 | 4.95 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Arcutis Biotherapeutics Inc | 376.07m | -16.14m | 3.07bn | 354.00 | -- | 16.12 | -- | 8.17 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Supernus Pharmaceuticals Inc | 718.95m | -38.55m | 3.17bn | 674.00 | -- | 2.98 | 59.59 | 4.40 | -0.6839 | -0.6839 | 12.70 | 18.48 | 0.5098 | 1.09 | 4.36 | -- | -2.73 | 2.01 | -3.52 | 2.67 | 89.63 | 87.96 | -5.36 | 4.66 | 1.66 | -- | -- | -- | 8.63 | 6.68 | -152.19 | -- | -- | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.24bn | 600.00 | 18.12 | 1.77 | 14.97 | 2.94 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Tarsus Pharmaceuticals Inc | 451.36m | -66.42m | 3.30bn | 370.00 | -- | 9.59 | -- | 7.30 | -1.61 | -1.61 | 10.81 | 8.07 | 0.9612 | 8.78 | 6.85 | 1,219,892.00 | -14.14 | -27.80 | -18.38 | -32.78 | 93.20 | 93.45 | -14.72 | -53.60 | 3.82 | -- | 0.1742 | -- | 146.71 | -- | 42.52 | -- | 84.92 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 677.56m | 59.01m | 3.52bn | 366.00 | 61.76 | 6.18 | 58.14 | 5.20 | 0.7448 | 0.7448 | 8.58 | 7.44 | 1.01 | 1.91 | 23.64 | 1,851,268.00 | 8.78 | 2.35 | 10.69 | 2.75 | 88.54 | 87.48 | 8.71 | 3.40 | 3.39 | -- | 0.00 | 0.00 | 60.09 | -- | 236.61 | -- | 40.84 | -- |
| Corcept Therapeutics Inc | 761.41m | 99.65m | 3.83bn | 730.00 | 43.32 | 5.88 | 37.96 | 5.03 | 0.8303 | 0.8303 | 6.35 | 6.11 | 0.908 | 1.03 | 13.39 | 1,043,023.00 | 11.88 | 17.68 | 14.54 | 20.76 | 98.30 | 98.47 | 13.09 | 20.88 | 2.85 | -- | 0.00 | 0.00 | 12.79 | 16.56 | -29.43 | -1.23 | -29.80 | -- |
| ADMA Biologics Inc | 510.17m | 146.93m | 3.95bn | 647.00 | 27.65 | 8.26 | 25.47 | 7.74 | 0.5996 | 0.5996 | 2.08 | 2.01 | 0.9168 | 1.15 | 4.90 | 788,520.90 | 26.40 | 9.62 | 29.75 | 10.91 | 57.39 | 44.75 | 28.80 | 12.51 | 3.74 | 37.09 | 0.1313 | 0.00 | 19.63 | 64.60 | -25.67 | -- | 12.46 | -- |
| Indivior Pharmaceuticals, Inc | 1.18bn | 122.00m | 4.00bn | 1.03k | 33.34 | -- | 27.02 | 3.39 | 0.9592 | 0.9592 | 9.20 | -1.66 | 0.8194 | 1.03 | 4.63 | 1,145,631.00 | 8.68 | -1.36 | 26.23 | -2.98 | 85.51 | 84.87 | 10.59 | -2.47 | 0.7938 | 9.33 | 2.80 | -- | 8.69 | 8.64 | 101.55 | -56.87 | 34.66 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 4.04bn | 68.00 | 97.48 | 4.19 | 48.79 | 16.08 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.33bn | 8.10k | 833.54 | -- | 14.53 | 1.48 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| TG Therapeutics Inc | 616.29m | 447.18m | 4.69bn | 399.00 | 10.59 | 7.05 | 10.50 | 7.62 | 2.78 | 2.78 | 3.82 | 4.17 | 0.7511 | 0.8534 | 2.83 | 1,544,579.00 | 54.50 | -3.81 | 64.04 | -4.57 | 83.66 | 87.01 | 72.56 | -7.46 | 3.29 | 4.61 | 0.2749 | -- | 87.32 | 426.73 | 1,812.41 | -- | -9.73 | -- |
| Mirum Pharmaceuticals Inc | 521.31m | -23.36m | 5.44bn | 369.00 | -- | 14.86 | 6,170.46 | 10.43 | -0.4783 | -0.4783 | 10.07 | 6.06 | 0.6889 | 4.24 | 5.17 | 1,412,770.00 | -3.09 | -19.72 | -3.96 | -23.84 | 80.77 | 78.68 | -4.48 | -43.34 | 2.55 | -13.32 | 0.4961 | -- | 54.74 | -- | 73.43 | -- | 33.50 | -- |
Data as of Mar 02 2026. Currency figures normalised to Indivior Pharmaceuticals Inc's reporting currency: US Dollar USD
48.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 16.82m | 13.47% |
| Oaktree Capital Management LPas of 31 Dec 2025 | 7.11m | 5.69% |
| Fuller & Thaler Asset Management, Inc.as of 31 Dec 2025 | 6.37m | 5.10% |
| Madison Avenue Partners LPas of 31 Dec 2025 | 6.28m | 5.03% |
| Two Seas Capital LPas of 31 Dec 2025 | 5.11m | 4.09% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.66m | 3.73% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.56m | 3.66% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 4.13m | 3.31% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 3.09m | 2.47% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 2.98m | 2.39% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
